take execut remain high pipelin asset start emerg beyond cf
invest summari reiter overweight rate pt
vertex today report fourth-quart result provid guidanc
view print quarter guidanc favor also think
expect street increas estim total revenu
higher end guidanc new
ep estim think compani execut
high level bring new pipelin asset clinic crux
thesi
think upcom triplet readout highli de-risk sinc
compani alreadi one tripl regimen look robust
think readout inform compani pick risk/
benefit profil triplet model sale tripl although
think compani could get approv faster expect model
sale launch price believ robust
benefit popul limit option
intrigu compani pain program
base-cas valuat think could next potenti late-stag
opportun vertex pay close attent strategi late-stag
develop plan current vertex complet three proof-of-concept studi
anoth readout expect patient acut pain think
compani may pursu opportun acut and/or neuropath pain develop
next-gener asset larger market
vertex begin bring asset intern pipelin clinic
also find notabl compani amass signific cash
come year vertex outlin three bucket potenti extern acquisit
includ complementari cystic fibrosi asset technolog tool like
crispr arbor deal complementari pipelin asset note
need on-market late-stag deal buy revenu growth would
agre signific revenu ep growth like one biggest
rare diseas product launch tripl top- bottom-lin
compound-annual-growth-rate basi estim growth respect
disclosur section may found page
use probability-adjust dcf valu vertex share assum discount rate
model revenu assum termin valu roughli
vertex valuat base termin valu reflect compani intern engin
risk overweight rate price target includ lack triple-combo success
efficaci safeti would limit vertex address cf popul unexpect
competit competitor data notabl galapago glpg ow cover merl
pipelin failur stall mid-stag pipelin beyond cf safeti event
non-gaap royalti collabor revenu
non-gaap revenu expens
net product revenu
net product revenu
net product revenu
total sg non-gaap
interest expens incom non-gaap
vertex global biotechnolog compani invest scientif innov creat transform medicin peopl seriou
life-threaten diseas
